Antiplatelet therapy in secondary stroke prevention

M. K. Crawford, Robert Talbert

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.

Original languageEnglish (US)
Pages (from-to)1609-1613
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number10
DOIs
StatePublished - 2001

Fingerprint

Secondary Prevention
Stroke
clopidogrel
Platelet Aggregation Inhibitors
Aspirin
Ticlopidine
Dipyridamole
Therapeutics
Cause of Death

Keywords

  • Antiplatelet
  • Aspirin
  • Clopidogrel
  • Dipyridamole
  • Stroke prevention
  • Thienopyridine ticlopidine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antiplatelet therapy in secondary stroke prevention. / Crawford, M. K.; Talbert, Robert.

In: Expert Opinion on Pharmacotherapy, Vol. 2, No. 10, 2001, p. 1609-1613.

Research output: Contribution to journalArticle

Crawford, M. K. ; Talbert, Robert. / Antiplatelet therapy in secondary stroke prevention. In: Expert Opinion on Pharmacotherapy. 2001 ; Vol. 2, No. 10. pp. 1609-1613.
@article{d0de1a58cd884c9db8a13cf7e751da9c,
title = "Antiplatelet therapy in secondary stroke prevention",
abstract = "Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.",
keywords = "Antiplatelet, Aspirin, Clopidogrel, Dipyridamole, Stroke prevention, Thienopyridine ticlopidine",
author = "Crawford, {M. K.} and Robert Talbert",
year = "2001",
doi = "10.1517/14656566.2.10.1609",
language = "English (US)",
volume = "2",
pages = "1609--1613",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Antiplatelet therapy in secondary stroke prevention

AU - Crawford, M. K.

AU - Talbert, Robert

PY - 2001

Y1 - 2001

N2 - Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.

AB - Stroke is the third leading cause of death in the United States. Antiplatelet agents are the mainstays of ischaemic stroke prevention. The therapies recommended for initial therapy include aspirin (50 - 325 mg) daily, the combination of aspirin (25 mg) and extended-release dipyridamole (200 mg) b.i.d., or clopidogrel (75 mg) daily. Ticlopidine 250 mg b.i.d. is approved for stroke prevention but is no longer a first-line therapy. This article reviews the literature on antiplatelet agents for secondary stroke prevention.

KW - Antiplatelet

KW - Aspirin

KW - Clopidogrel

KW - Dipyridamole

KW - Stroke prevention

KW - Thienopyridine ticlopidine

UR - http://www.scopus.com/inward/record.url?scp=0034757474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034757474&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.10.1609

DO - 10.1517/14656566.2.10.1609

M3 - Article

C2 - 11825303

AN - SCOPUS:0034757474

VL - 2

SP - 1609

EP - 1613

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -